Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | TPMT | P51580 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 7/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865237 | 0.87 | LMNA (0.65) | LMNACASP6TSHRTPMTALDH1A1 | |
| SCHEMBL3707317 | 0.86 | PARP1 (0.63) | LMNACASP6PARP1TSHRALDH1A1 | |
| SCHEMBL4632273 | 0.82 | LMNA (0.64) | LMNACASP6TSHRTPMTALDH1A1 | |
| SCHEMBL3704229 | 0.81 | PARP1 (0.49) | LMNACASP6PARP1ALDH1A1MAPT | |
| SCHEMBL2720416 | 0.81 | VCAM1 (0.49) | LMNAPARP1TPMTALDH1A1MAPT | |
| SCHEMBL452336 | 0.81 | ALDH1A1 (0.58) | LMNACASP6TSHRTPMTALDH1A1 | |
| SCHEMBL3767693 | 0.81 | CASP6 (0.53) | LMNACASP6PARP1TSHRTPMT | |
| SCHEMBL11616525 | 0.80 | CASP6 (0.60) | LMNACASP6PARP1TSHRTPMT | |
| SCHEMBL1509549 | 0.79 | TSHR (0.60) | LMNACASP6TSHRTPMTALDH1A1 | |
| SCHEMBL1759017 | 0.79 | LMNA (0.56) | LMNACASP6TSHRTPMTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289785-A1 | INDOLE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | MITOIMMUNE THERAPEUTICS INC. (KR) | 2025-09-18 | — | — | US | disclosed |
| CN-114080383-B | Process for preparing indole or indazole compounds | 株式会社LG化学 | 2024-07-23 | — | — | CN | disclosed |
| EP-4382524-A1 | INDOLE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | MitoImmune Therapeutics Inc. (KR) | 2024-06-12 | — | — | EP | disclosed |
| CN-114080382-B | Process for preparing indole or indazole compounds | 株式会社LG化学 | 2024-05-24 | — | — | CN | disclosed |
| EP-3971184-B1 | METHOD FOR PREPARING INDOLE OR INDAZOLE COMPOUND | LG CHEMICAL LTD (KR) | 2024-04-03 | — | — | EP | disclosed |
| CN-117794922-A | Indole derivatives, process for their preparation and their use | 水疗免疫疗法有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023013996-A1 | INDOLE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | 주식회사 미토이뮨테라퓨틱스 | 2023-02-09 | — | — | WO | disclosed |
| EP-3971183-A1 | METHOD FOR PRODUCING INDOLE OR INDAZOLE COMPOUND | LG Chem, Ltd. (KR) | 2022-03-23 | — | — | EP | disclosed |
| EP-3971184-A1 | METHOD FOR PREPARING INDOLE OR INDAZOLE COMPOUND | LG Chem, Ltd. (KR) | 2022-03-23 | — | — | EP | disclosed |
| CN-114080382-A | Process for preparing indole or indazole compounds | 株式会社LG化学 | 2022-02-22 | — | — | CN | disclosed |
| CN-114080383-A | Process for preparing indole or indazole compounds | 株式会社LG化学 | 2022-02-22 | — | — | CN | disclosed |
| WO-2020256429-A1 | METHOD FOR PREPARING INDOLE OR INDAZOLE COMPOUND | 주식회사 엘지화학 | 2020-12-24 | — | — | WO | disclosed |
| WO-2020256430-A1 | METHOD FOR PRODUCING INDOLE OR INDAZOLE COMPOUND | 주식회사 엘지화학 | 2020-12-24 | — | — | WO | disclosed |
| WO-2010093191-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2010-08-19 | — | — | WO | disclosed |
| US-5958973-A | Polyhydroxy benzoic acid derivatives and their use as neuraminidase inhibitors | GILEAD SCIENCES, INC. (US) | 1999-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289785-A1 | INDOLE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | AIFM2, AIFM1, HMOX1 | LMNA 1625/4885CASP6 145/4885PARP1 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.